Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 403

Sort by

Sort Order Select

Journal Articles

CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18

Blood blood.2025031006.

https://doi.org/10.1182/blood.2025031006

Published: 2025

Includes: Supplemental data

Journal Articles

Clonal evolution of pediatric Acute Myeloid Leukemia

Masayuki Umeda, Pandurang Kolekar, Anna Huskey, Shruthi Suryaprakash, Hanxia Li, Tamara Westover, Jing Ma, Mike Walsh, Guangchun Song, Yanling Liu, Quang Tran, Seth Karol, Hiroto Inaba, Jeffrey Rubnitz, Raul Ribeiro, Xiaotu Ma, Jeffery Klco

Blood (2025) 146 (Supplement 1): 1721.

https://doi.org/10.1182/blood-2025-1721

Published: 2025

Journal Articles

FLT3-F691L confers kinase-independent resistance via Grb2-dependent MAPK signaling in AML

LaQuita Jones, Akhtar Khadaroo, Riya Tiwari, Kwangmin Choi, Mike Adam, Mark Wunderlich, Cody Stillwell, Christina Sexton, William Seibel, Greg Tawa, Scott Hoyt, Craig Thomas, Daniel Starczynowski

Blood (2025) 146 (Supplement 1): 5049.

https://doi.org/10.1182/blood-2025-5049

Published: 2025

Journal Articles

Real-world comparison of treatment outcomes between BCL2i and 2nd generation BTKi therapy in first-line CLL patients

Rushir Choksi, Aliakbar Dadla, Thomas Weart, Brian Mulherin, Taral Patel, Fred Kudrik, Tejvir Singh, Anna Rui, Gino Cioffi, Don Parris, Mike Gart, Janet Donegan, Lisa Morere, Lisa Kunst, Lindsay Aton, Poras Dave, Doug Kanovsky, Jeffrey Scott, Jing-Zhou Hou

Blood (2025) 146 (Supplement 1): 4505.

https://doi.org/10.1182/blood-2025-4505

Published: 2025

Journal Articles

Safety and efficacy results from A phase 1b study of R289, a dual irak 1/4 inhibitor, in patients with Relapsed/Refractory (R/R) lower risk myelodysplastic syndrome (LR-MDS).

Guillermo Garcia-Manero, Yazan Madanat, Mikkael Sekeres, Hetty Carraway, Mike Cusnir, James McCloskey, Kiran Naqvi, Gary Schiller, Frank Hsu, Toufigh Gordi, Lisa Rojkjaer, Lewis R Silverman

Blood (2025) 146 (Supplement 1): 489.

https://doi.org/10.1182/blood-2025-489

Published: 2025

Journal Articles

JAK2 signalling to HNRNPA1 represses retrotransposon activity in haematopoietic stem cells.

Jeremy Deuel, Andrejs Makarovs, Sheidasadat Goosheh, George Winder, Hisham Mohammed, Jason Carroll, Mike Chapman, Chiraag Kapadia, Peter Campbell, Jyoti Nangalia, Elisa Laurenti, Constanze Schneider, Thomas Oellerich, Anthony Green, Stephen Loughran

Blood (2025) 146 (Supplement 1): 3149.

https://doi.org/10.1182/blood-2025-3149

Published: 2025

Journal Articles

Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy

Joseph Franz, Dhaval Mehta, Kathleen Dorritie, Rushir Choksi, Taya Salman, Mike Gart, Lisa Kunst, Harshal Dave, Kristen Henn, Prashanth Jain, Brandon Wang, Prateesh Varughese, Lisa Morere, Jeffrey Scott, Paul Richardson

Blood (2025) 146 (Supplement 1): 8120.

https://doi.org/10.1182/blood-2025-8120

Published: 2025

Journal Articles

Real-world patient characteristics, treatment patterns, and outcomes in patients with myelodysplastic syndromes

Mike Yang, Shiyun Zhu, Kenneth Poon, Raymond Lui, Gary Okano, Tony Wang, Vincent Zhang, Jingrong Yang, Samantha Slaff, Ryan Stevenson

Blood (2025) 146 (Supplement 1): 7398.

https://doi.org/10.1182/blood-2025-7398

Published: 2025

Journal Articles

Factors impacting treatment choice with a CD38 antibody, immunomodulator, proteasome inhibitor, and dexamethasone in first line multiple myeloma patients: A real-world US study

Joseph Franz, Joseph Mikhael, Dhaval Mehta, Rushir Choksi, Taya Salman, Mike Gart, John Li, Harshal Dave, Lisa Kunst, Kristen Henn, Prashanth Jain, Brandon Wang, Prateesh Varughese, Lisa Morere, Jeffrey Scott, Paul Richardson

Blood (2025) 146 (Supplement 1): 3988.

https://doi.org/10.1182/blood-2025-3988

Published: 2025

Journal Articles

A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)

Blood (2025) 146 (Supplement 1): 248.

https://doi.org/10.1182/blood-2025-248

Published: 2025

Journal Articles

UBTF tandem duplications generate a nuclear export signal motif that drives an XPO1 dependency in leukemia

Blood (2025) 146 (Supplement 1): 986.

https://doi.org/10.1182/blood-2025-986

Published: 2025

Journal Articles

A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)

Blood (2025) 146 (Supplement 1): 4052.

https://doi.org/10.1182/blood-2025-4052

Published: 2025

Journal Articles

Outcomes of mecom rearranged AML undergoing intensive chemotherapy in the NCRI AML17 and AML19 trials.

Mike Dennis, Jad Othman, Joanna Canham, Ian Thomas, Sean Johnson, Nick Telford, Beth Harrison, Jeyaprakash Ramachandran, James Cavenagh, Claire Arnold, Claus Marcher, Richard Kelly, Mhairi Copland, Alan Burnett, Richard Dillon, Nigel Russell

Blood (2025) 146 (Supplement 1): 3435.

https://doi.org/10.1182/blood-2025-3435

Published: 2025

Journal Articles

Checkpoint inhibitors improve progression free survival after autologous transplant despite poorer pre-transplant response

Jack Taylor-Stuart, Mark Ethell, Mike Potter, Sandra Easdale, Chloe Anthias, Caroline Furness, David Cunningham, Ian Chau, Dima El-Sharkawi, Sunil Iyengar, Emma Nicholson

Blood (2025) 146 (Supplement 1): 7134.

https://doi.org/10.1182/blood-2025-7134

Published: 2025

Journal Articles

Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia

Jing-Zhou Hou, Rushir Choksi, Gregory Maglinte, Xiaoliang Wang, Anna Rui, Beverly Chigarira, Lindsay Aton, Melissa Hagan, Lisa Morere, Mike Gart, Rhys Williams, Daniel Ermann

Blood (2025) 146 (Supplement 1): 6317.

https://doi.org/10.1182/blood-2025-6317

Published: 2025

Journal Articles

Characterizing the In Vivo impact of inflammation on Samd9l hematopoietic phenotypes.

Melvin Thomas, Emily Xiong, Tamara Westover, Mike Walsh, Jing Ma, Chandra Rolle, Yonghui Ni, Steven Burden, Laura Janke, Stanley Pounds, Jeffery Klco

Blood (2025) 146 (Supplement 1): 2055.

https://doi.org/10.1182/blood-2025-2055

Published: 2025

Journal Articles

Genomic and phenotypic impact of FHD-286–induced inhibition of SMARCA4/2 in patients with relapsed/refractory myeloid malignancies

Mike Collins, David Lahr, Eytan Stein, Courtney DiNardo, Ashwin Kishtagari, Brian Ball, Kim Horrigan, Alexis Khalil, Katie D'Aco, Mia Bosinger, Salih Topal, Nicholas Spidale, Alfonso Quintas-Cardama, Gromoslaw Smolen

Blood (2025) 146 (Supplement 1): 655.

https://doi.org/10.1182/blood-2025-655

Published: 2025

Journal Articles

primary breast lymphoma: A 10-year retrospective case series on clinical features, diagnostic imaging, and outcomes from a diverse population treated at mount sinai medical center in miami beach

Carla Romagnoli, Leily Santos-Carrion, Alexandra Lyubimova, Evelyn Goya Balaguer, Oleg Gligich, Michael Schwartz, Mike Cusnir, Jacqueline Barrientos

Blood (2025) 146 (Supplement 1): 8105.

https://doi.org/10.1182/blood-2025-8105

Published: 2025

Journal Articles

Quality initiative in first-line chronic lymphocytic leukemia /small lymphocytic lymphoma assessing the use of 2nd generation BTKi therapy and impact on cardiac medical conditions patients experience on treatment

Jing-Zhou Hou, Tejvir Singh, Wesley Falconer, Patrick Travis, Olalekan Ajayi, Jason Stinnett, Kyle Kitchen, Anna Rui, Mike Gart, Lisa Kunst, Lindsay Aton, Poras Dave, Doug Kanovsky, Brandon Wang, Prateesh Varughese, Robert Geller, Jeffrey Scott, Rushir Choksi

Blood (2025) 146 (Supplement 1): 7934.

https://doi.org/10.1182/blood-2025-7934

Published: 2025

Journal Articles

Evaluation of real-world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies

Blood (2025) 146 (Supplement 1): 6286.

https://doi.org/10.1182/blood-2025-6286

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18

Clonal evolution of pediatric Acute Myeloid Leukemia

FLT3-F691L confers kinase-independent resistance via Grb2-dependent MAPK signaling in AML

Real-world comparison of treatment outcomes between BCL2i and 2nd generation BTKi therapy in first-line CLL patients

Safety and efficacy results from A phase 1b study of R289, a dual irak 1/4 inhibitor, in patients with Relapsed/Refractory (R/R) lower risk myelodysplastic syndrome (LR-MDS).

JAK2 signalling to HNRNPA1 represses retrotransposon activity in haematopoietic stem cells.

Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy

Real-world patient characteristics, treatment patterns, and outcomes in patients with myelodysplastic syndromes

Factors impacting treatment choice with a CD38 antibody, immunomodulator, proteasome inhibitor, and dexamethasone in first line multiple myeloma patients: A real-world US study

A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)

UBTF tandem duplications generate a nuclear export signal motif that drives an XPO1 dependency in leukemia

A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)

Outcomes of mecom rearranged AML undergoing intensive chemotherapy in the NCRI AML17 and AML19 trials.

Checkpoint inhibitors improve progression free survival after autologous transplant despite poorer pre-transplant response

Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia

Characterizing the In Vivo impact of inflammation on Samd9l hematopoietic phenotypes.

Genomic and phenotypic impact of FHD-286–induced inhibition of SMARCA4/2 in patients with relapsed/refractory myeloid malignancies

primary breast lymphoma: A 10-year retrospective case series on clinical features, diagnostic imaging, and outcomes from a diverse population treated at mount sinai medical center in miami beach

Quality initiative in first-line chronic lymphocytic leukemia /small lymphocytic lymphoma assessing the use of 2nd generation BTKi therapy and impact on cardiac medical conditions patients experience on treatment

Evaluation of real-world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only